Roche/Genentech eye US diabetic retinopathy market for Lucentis
This article was originally published in Scrip
Executive Summary
Roche subsidiary Genentech on 8 August said it had submitted a supplemental biologics application (sBLA) to the FDA seeking approval to market Lucentis (ranibizumab injection) as a treatment for diabetic retinopathy, the most common diabetic eye disease, affecting nearly 8 million Americans.